Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 118Genitourinary 107Gastrointestinal 73Endocrine 59CNS 48NET 38Lymphoid 38Thoracic 29Tumor-Agnostic 26Other hematologic neoplasm 26Head & Neck 25Sarcoma 23Other solid neoplasm 22Gynecologic 21Dermatologic 19Plasma cell 11Myeloid 6Other neoplasm 1Other 1Classical hematology 1

Conditions

Somatostatinoma 1Mucositis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Islet Cell 1Breast Neoplasms 1

Interventions

Exercise 27Metformin 24Methods 14Radiotherapy 13Early Intervention, Educational 13Educational Status 12Counseling 12Surveys and Questionnaires 10Standard of Care 10Nutrition Assessment 9Resistance Training 8Diet Therapy 8Cisplatin 8naloxegol 7Tirzepatide 7Diet 7alvimopan 6Psychiatric Rehabilitation 6Fibroblast Growth Factor 7 6Caloric Restriction 6Radiation 5Low-Level Light Therapy 5Liraglutide 5Injections 5Exenatide 5Dexamethasone 5Cryotherapy 5semaglutide 4angiotensin I (1-7) 4Vitamin D 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Everolimus × Other × Clear all
NCT02273752 2017-02-03

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Emory University

Phase 2 Terminated
2 enrolled 5 charts
BreastEndocrineGenitourinaryOther

Breast Neoplasms, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡